EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database

Guilhem Solé iD, Jean Philippe Camdessanché iD, Shahram Attarian iD, Mariana Ciumas, Cécile Blein iD, Benjamin Grenier iD, Eléonore Herquelot iD, Andoni Echaniz-Laguna iD

European Journal of Neurology · 2026

DOI: 10.1111/ene.70504 ↗

At a glance

Beobachtungsstudie in European Journal of Neurology, 2026. Written by Guilhem Solé and 7 co-authors. Institution: Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department, Pellegrin Hospital, Bordeaux University Hospitals, Filnemus, Eur…. Major MEDLINE topics: Myasthenia Gravis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Contraindications, Drug. Cited 3 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: argenx.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Clinical guidelines for treating myasthenia gravis (MG) recommend avoiding certain therapies because of a risk of exacerbating MG. We evaluated use of statins and other classically contraindicated therapies and their impact on healthcare outcomes among patients with MG in France.

Methods

This was an observational, retrospective, longitudinal cohort study using data from the French national health insurance database. Adult patients with MG‐related claims from 2013 to 2020 were included. The first MG claim date was the index date, with follow‐up until end‐of‐study or death. Multivariable regression models evaluated the risk of intensive care unit (ICU) admission for MG or death during periods of exposure versus nonexposure to contraindicated treatments.

Results

Of 14,459 individuals with MG, 12,954 (89.6%) received a contraindicated treatment during follow‐up, and 4160 (28.8%) received statins. In multivariable regression analyses, exposure to any contraindicated treatment was not significantly associated with risk of ICU admission for MG (hazard ratio [HR] 1.038; 95% confidence interval [CI] 0.968–1.113; p = not significant) but was associated with significantly higher risk of death (HR 1.167; 95% CI 1.075–1.266; p < 0.001) versus nonexposure. In contrast, statins were associated with a greater risk of ICU admission (HR 1.133; 95% CI 1.065–1.205; p < 0.001) but lower risk of death (HR 0.626; 95% CI 0.565–0.694; p < 0.001).

Conclusion

This large, real‐world study suggests that for some contraindicated medications, including statins, longer‐term mortality benefits are likely to outweigh short‐term risks of exacerbating MG.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisHydroxymethylglutaryl-CoA Reductase InhibitorsContraindications, DrugHumansFemaleMaleFranceMiddle AgedRetrospective StudiesAgedDatabases, FactualAdultLongitudinal StudiesIntensive Care Units

Author keywords

contraindicationshospitalizationmortalitymyasthenia gravisstatins

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Authors and institutions

  • Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department, Pellegrin Hospital, Bordeaux University Hospitals, Filnemus, Euro-NMD, Bordeaux, France.
  • Department of Neurology, Neuromuscular Disease Reference Center, Hôpital Nord, University Hospital of Saint-Étienne, Saint-Étienne, France.
  • Reference Center for Neuromuscular Disease and ALS, Timone University Hospital, Aix-Marseille University, CHU Timone, Marseille, France.
  • argenx, Ghent, Belgium.
  • Heva, Lyon, France.
  • Department of Neurology, APHP, CHU de Bicêtre, INSERM U1195, Paris-Saclay University, Le Kremlin-Bicêtre, France.

ORCID profiles: Guilhem Solé, Jean Philippe Camdessanché, Shahram Attarian, Cécile Blein, Benjamin Grenier, Eléonore Herquelot, Andoni Echaniz-Laguna

Funding

  • argenx

Cite

APA

Solé, G., Camdessanché, J. P., Attarian, S., Ciumas, M., Blein, C., Grenier, B., Herquelot, E., & Echaniz-Laguna, A. (2026). Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database. European Journal of Neurology. https://doi.org/10.1111/ene.70504

Vancouver

Solé G, Camdessanché JP, Attarian S, Ciumas M, Blein C, Grenier B, et al. Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database. European Journal of Neurology. 2026. doi:10.1111/ene.70504

BibTeX
@article{Sol2026,
  author = {Solé, Guilhem and Camdessanché, Jean Philippe and Attarian, Shahram and Ciumas, Mariana and Blein, Cécile and Grenier, Benjamin and Herquelot, Eléonore and Echaniz-Laguna, Andoni},
  title = {Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70504}
}
Start for free →